SARS-CoV-2 omicron breakthrough infections in patients with multiple sclerosis.

Zoé Léonie Elise van KempenEileen W StalmanMaurice SteenhuisLaura Y L KummerKoos P J van DamMaarten F WilbrinkAnja Ten BrinkeS Marieke van HamTaco KuijpersTheo RispensFilip EftimovLuuk WieskeJoep Killesteinnull null

Published in: Journal of neurology, neurosurgery, and psychiatry (2022)

SARS-COV-2 omicron breakthrough infections are more prevalent in patients with MS on anti-CD20 therapies and S1PR modulators compared with other patients with MS, which correlated with decreased humoral responses after vaccination. Humoral responses after infection were higher in S1PR modulator-treated patients in comparison to patients on anti-CD20 therapies, suggesting that immunological protection from contracting infection or repeated exposures may differ between these therapies.

Keyphrases

sars cov
end stage renal disease
newly diagnosed
immune response
chronic kidney disease
mass spectrometry
multiple sclerosis
prognostic factors
ms ms
respiratory syndrome coronavirus
small molecule
air pollution
patient reported
clinical evaluation